High-plex spatial proteomic profiling of immunotherapy response groups in head and neck cancer identifies tissues signatures associated with therapy response - Visiopharm

Resources / High-plex spatial proteomic profiling of immunotherapy response groups in head and neck cancer identifies tissues signatures associated with therapy response

Phenoplex™

High-plex spatial proteomic profiling of immunotherapy response groups in head and neck cancer identifies tissues signatures associated with therapy response

Originally presented at SITC 2022

Details

Download now Details

Background

Head and neck squamous cell carcinoma (HNSCC) frequently presents with advanced disease and a poor prognosis. Immunotherapy has shown promising results in patients with metastatic or recurrent (M/R) disease; however, it is only effective in a subset of individuals. Recently, spatial profiling of the tumour microenvironment in HNSCC provided valuable information and new insights into various immune subsets as well as cellular and molecular interactions involved in
immunotherapy response or resistance.

Authors and institutions

Habib Sadeghirad¹, Ning Liu², James Monkman¹, Chin Wee Tan², Caroline Cooper¹,³, Sarah E Church⁴, Dan Winkowski⁵, Fabian Schneider⁵, Jeppe Thaagard⁵, James Mansfield⁵, Ken O’Byrne³, Melissa Davis², Brett Hughes⁶, Arutha Kulasinghe¹

1. The University of Queensland Diamantina Institute, The University of Queensland, Woolloongabba, QLD, Australia.
2. The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.
3. Princess Alexandra Hospital, Woolloongabba, QLD, Australia.
4. Nanostring Technologies, USA.
5. Visiopharm, Denmark.
6. Royal Brisbane and Women’s Hospital, Herston, QLD, Australia